Mesothelioma Clinical Trials Overview > Mesothelioma Clinical Trial List
Everolimus (RAD001) for the Treatment of Malignant Pleural Mesothelioma With Merlin/NF2 Loss as a Biomarker to Predict Sensitivity
| Conditions: | Malignant Pleural Mesothelioma |
| Start Date: | December 1, 2009 |
| Phase: | Phase II |
| Status: | Recruiting |
| NCT ID: | NCT01024946 |
| Study Type: | Interventional |
| Intervention: | Drug: everolimus |
| Study Design: | Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment |
| Results: | No Results Available |
| Sponsors: | Memorial Sloan-Kettering Cancer Center|Novartis Pharmaceuticals |
| Ages: | Adult|Senior |
| Enrollment: | 39 |
| Funded By: | Other|Industry |
| First Received: | December 2, 2009 |
| End Date: | December 1, 2011 |
| Last Updated: | December 10, 2010 |
| Last Verified: | December 1, 2010 |
Mesothelioma
Lawsuit Evaluation
Lawsuit Evaluation
